ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,267.84
-0.74%
Dow Jones
39,065.26
-1.53%
US Dollar vs MXN
16.7281
0.38%
Brent Oil
81.25
-0.34%
Bitcoin
67,742.25
-1.96%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
Símbolo desconocido
Fecha:
Ordernar por:
FechaHoraFuenteTítuloSímboloCompañía
23/05/202416:00Business WireGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:GMABGenmab AS
23/05/202416:00Business WireMerck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
23/05/202416:00GlobeNewswire Inc.IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual MeetingNASDAQ:INABIN8bio Inc
23/05/202416:00Business WireLegend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHANASDAQ:LEGNLegend Biotech Corporation
23/05/202416:00Business WireSOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting
23/05/202416:00GlobeNewswire Inc.Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
23/05/202416:00GlobeNewswire Inc.Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual MeetingTG:2GHMerus NV
23/05/202416:00GlobeNewswire Inc.Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:BPTHBio Path Holdings Inc
23/05/202416:00GlobeNewswire Inc.Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024NASDAQ:EVAXEvaxion Biotech AS
23/05/202416:00Business WireObsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
23/05/202416:00GlobeNewswire Inc.Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual MeetingNASDAQ:MURAMural Oncology PLC
23/05/202416:00Business WireDentalcorp Announces Annual General Meeting Voting ResultsTSX:DNTLdentalcorp Holdings Ltd
23/05/202416:00GlobeNewswire Inc.MAQUIA CAPITAL ACQUISITION CORPORATION AND IMMERSED INC. MUTUALLY AGREE TO TERMINATE BUSINESS COMBINATION AGREEMENTNASDAQ:MAQCMaquia Capital Acquisition Corporation
23/05/202416:00GlobeNewswire Inc.Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
23/05/202416:00Business WireKlaviyo to Present at the William Blair Growth Stock ConferenceNYSE:KVYOKlaviyo Inc
23/05/202415:59Edgar (US Regulatory)Form 8-K - Current reportNYSE:RCUSArcus Biosciences Inc
23/05/202415:59Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GNLXGenelux Corporation
23/05/202415:58Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNYSE:BACBank of America Corporation
23/05/202415:58Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NYSE:GS-JGoldman Sachs Group Inc
23/05/202415:58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DASHDoorDash Inc
23/05/202415:58Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LMFALM Funding America Inc
23/05/202415:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CCOICogent Communications Holdings Inc
23/05/202415:56Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:GHSIGuardion Health Sciences Inc
23/05/202415:55GlobeNewswire Inc.Park Aerospace Corp. Announces Date of Fiscal Year Earnings Release and Conference CallNYSE:PKEPark Aerospace Corp
23/05/202415:55Business WireSuperati i 100 milioni di marchi di fabbrica globali attivi in soli tre anni, secondo Corsearch
23/05/202415:55Business WireCorsearch: Weltweite Zahl aktiver Marken passiert 100-Millionen-Marke in zwei Jahren
23/05/202415:54Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:AMATApplied Materials Inc
23/05/202415:52Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:LABPLandos Biopharma Inc
23/05/202415:52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:HUBCZHub Cyber Security Ltd
23/05/202415:50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IVVDInvivyd Inc

Su Consulta Reciente

BIT
P20O79
NLBNPIT20O79 20240516 85
EU
ACALR
Credit Agricole Public S...
GATE
HIGHUSDT
Highstreet token
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados